iCFO CAPITAL · ECOSYSTEM SHOWCASE
Live Web Event for Investors and Founders
iCapOS provides technology and diligence infrastructure for review purposes only. Nothing on this platform is investment advice, a recommendation, or a guarantee of funding, investor participation, allocations, returns, or liquidity. Private offerings are risky and may result in loss of capital. Investors must conduct independent due diligence and issuers should obtain appropriate legal review.
Investors
21Founders
13Auditorium: Experience our prequalified deal flows, learn from dynamic presentations, and engage with experts through interactive Q&A sessions.
Inside the Investor’s Mind – Investor Challenge Series is a monthly, investor-grade talk show designed to reveal how CEOs think, decide, and lead under real-world pressure. Each episode features a candid conversation with a CEO, followed by a live investor panel that asks the kinds of questions typically reserved for private diligence discussions. The panel addresses real-world challenges head-on, bringing the unfiltered reality of the investor perspective into the open.
NutriFlex AI solves fragmented health data and generic wellness programs that fail to turn biometric signals into timely, personalized action. Our AI-powered platform transforms wearable data—including sleep, stress, activity, and recovery signals—into adaptive, real-time recommendations that help individuals and organizations improve health, performance, and well-being.
Impervitex solves the massive thermal, environmental, and electronic vulnerabilities in conventional textiles without requiring expensive custom manufacturing or fabric re-engineering. We provide an asset-light Deep Tech Chemistry Platform that programs multi-spectral IR masking, thermal insulation, and EMP shielding directly into existing fabrics using proprietary chemical building blocks. Operating on a high-margin license-per-yard yield model, we enable commercial and defense partners to deploy advanced textile intelligence at scale with zero client-side inventory risk.
Points reward participation — status, not prizes.
Presenter
Dr. Paul is a Founding Partner and Chief Executive Officer of NovaRhythm Biosciences, a biotechnology company focused on developing transformative therapies for cardiac arrhythmias. He brings more than 40 years of experience spanning cardiovascular research, translational medicine, drug development, and biotechnology company leadership. Previously, he co-founded AnaBios Corporation, where he helped build a leading human tissue translational research platform serving major pharmaceutical and biotechnology companies worldwide.
Company
NovaRhythm Biosciences, Inc. is a cardiovascular biotechnology company developing SAR-297871, a highly selective TASK-1 inhibitor for the treatment of atrial fibrillation. The company holds an exclusive worldwide license from Sanofi for the program, which is supported by decades of research, extensive preclinical and human translational data, and approximately $200 million of prior investment. NovaRhythm's strategy is to complete IND-enabling studies and a Phase 1 clinical trial, creating a Phase 2-ready asset positioned for partnership or acquisition by a major pharmaceutical company. The company is focused on addressing a significant unmet medical need while creating substantial value for patients and investors.
Presenter
Steve is a tech visionary, former CEO, and the strategic force driving LivIQ’s advanced "Compliance by Design" infrastructure. Collaborating closely with his co-founder Christopher, he bridges the gap between cutting-edge Web3/DLT principles and scalable, decentralized population health platforms. For today’s iCFO session, Steve is showcasing how LivIQ’s automated data pipelines and bi-coastal logistics are redefining the future of precision medicine.
Company
LivIQ is a tech-first clinical infrastructure firm redefining decentralized diagnostics through an automated, "Compliance by Design" data pipeline. By combining painless collection hardware with a hybrid Web2.5 architecture, the company securely separates patient identity from clinical data to deliver audit-ready, FDA/RWE-grade metrics today, while positioning advanced data intelligence and Web3 decentralization on the immediate product roadmap. Supported by a dual-hub fulfillment model in Phoenix and Greenville, SC, alongside high-impact onsite activation teams, LivIQ enables partners to deploy any diagnostic, anywhere, with total data integrity and zero friction.